Pediatric patients exhibited high risk for severe avian influenza A/H5N1, suggesting clinical therapeutic and vaccine trials should be prioritized in this population.

Remdesivir was associated with a significant survival benefit and reduced risk for rehospitalization among inpatients with COVID-19 infection.